106 related articles for article (PubMed ID: 24694365)
1. Inhibitor binding to Hsp90: a review of thermodynamic, kinetic, enzymatic, and cellular assays.
Petrikaite V; Matulis D
Curr Protein Pept Sci; 2014 May; 15(3):256-82. PubMed ID: 24694365
[TBL] [Abstract][Full Text] [Related]
2. Thermodynamics of aryl-dihydroxyphenyl-thiadiazole binding to human Hsp90.
Kazlauskas E; Petrikaitė V; Michailovienė V; Revuckienė J; Matulienė J; Grinius L; Matulis D
PLoS One; 2012; 7(5):e36899. PubMed ID: 22655030
[TBL] [Abstract][Full Text] [Related]
3. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors.
Sharp SY; Boxall K; Rowlands M; Prodromou C; Roe SM; Maloney A; Powers M; Clarke PA; Box G; Sanderson S; Patterson L; Matthews TP; Cheung KM; Ball K; Hayes A; Raynaud F; Marais R; Pearl L; Eccles S; Aherne W; McDonald E; Workman P
Cancer Res; 2007 Mar; 67(5):2206-16. PubMed ID: 17332351
[TBL] [Abstract][Full Text] [Related]
4. Thermodynamic, kinetic, and structural parameterization of human carbonic anhydrase interactions toward enhanced inhibitor design.
Linkuvienė V; Zubrienė A; Manakova E; Petrauskas V; Baranauskienė L; Zakšauskas A; Smirnov A; Gražulis S; Ladbury JE; Matulis D
Q Rev Biophys; 2018 Jan; 51():e10. PubMed ID: 30912486
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.
Wright L; Barril X; Dymock B; Sheridan L; Surgenor A; Beswick M; Drysdale M; Collier A; Massey A; Davies N; Fink A; Fromont C; Aherne W; Boxall K; Sharp S; Workman P; Hubbard RE
Chem Biol; 2004 Jun; 11(6):775-85. PubMed ID: 15217611
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
[TBL] [Abstract][Full Text] [Related]
7. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
8. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
9. Thermodynamic Analysis of the Geldanamycin-Hsp90 Interaction in a Whole Cell Lysate Using a Mass Spectrometry-Based Proteomics Approach.
Xu Y; Wallace MA; Fitzgerald MC
J Am Soc Mass Spectrom; 2016 Oct; 27(10):1670-6. PubMed ID: 27530778
[TBL] [Abstract][Full Text] [Related]
10. Thermodynamics of radicicol binding to human Hsp90 alpha and beta isoforms.
Zubrienė A; Gutkowska M; Matulienė J; Chaleckis R; Michailovienė V; Voroncova A; Venclovas C; Zylicz A; Zylicz M; Matulis D
Biophys Chem; 2010 Nov; 152(1-3):153-63. PubMed ID: 20943306
[TBL] [Abstract][Full Text] [Related]
11. Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization.
Davies NG; Browne H; Davis B; Drysdale MJ; Foloppe N; Geoffrey S; Gibbons B; Hart T; Hubbard R; Jensen MR; Mansell H; Massey A; Matassova N; Moore JD; Murray J; Pratt R; Ray S; Robertson A; Roughley SD; Schoepfer J; Scriven K; Simmonite H; Stokes S; Surgenor A; Webb P; Wood M; Wright L; Brough P
Bioorg Med Chem; 2012 Nov; 20(22):6770-89. PubMed ID: 23018093
[TBL] [Abstract][Full Text] [Related]
12. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin.
Bagatell R; Beliakoff J; David CL; Marron MT; Whitesell L
Int J Cancer; 2005 Jan; 113(2):179-88. PubMed ID: 15455381
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
[TBL] [Abstract][Full Text] [Related]
14. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Hsf1 activity by novobiocin and geldanamycin.
Conde R; Belak ZR; Nair M; O'Carroll RF; Ovsenek N
Biochem Cell Biol; 2009 Dec; 87(6):845-51. PubMed ID: 19935870
[TBL] [Abstract][Full Text] [Related]
16. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity.
Rowlands MG; Newbatt YM; Prodromou C; Pearl LH; Workman P; Aherne W
Anal Biochem; 2004 Apr; 327(2):176-83. PubMed ID: 15051534
[TBL] [Abstract][Full Text] [Related]
17. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins.
Marcu MG; Schulte TW; Neckers L
J Natl Cancer Inst; 2000 Feb; 92(3):242-8. PubMed ID: 10655441
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs.
Geng K; Liu H; Song Z; Zhang C; Zhang M; Yang H; Cao J; Geng M; Shen A; Zhang A
Eur J Med Chem; 2018 May; 152():76-86. PubMed ID: 29698859
[TBL] [Abstract][Full Text] [Related]
19. Inside the Hsp90 inhibitors binding mode through induced fit docking.
Lauria A; Ippolito M; Almerico AM
J Mol Graph Model; 2009 Feb; 27(6):712-22. PubMed ID: 19084447
[TBL] [Abstract][Full Text] [Related]
20. Binding of natural and synthetic inhibitors to human heat shock protein 90 and their clinical application.
Petrikaitė V; Matulis D
Medicina (Kaunas); 2011; 47(8):413-20. PubMed ID: 22123555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
